Saturday, May 18, 2002

James Metz, MD, Editor-in-Chief and Maggie Hampshire, RN, BSN, OCN, Managing Editor, at the OncoLink Booth

Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from INT 0114 Presenter: M O'ConnellPresenter's Affiliation: National Intergroup TrialType of Session: ScientificBackground Although rectal cancer is usually an aggressive cancer, the resection of metastatic disease is thought to be efficacious. Although this...
Caelyx (Ca) And Carboplatin (Pa) In Patients With Advanced Ovarian Cancer In Late Relapse (> 6 Months) (AOCLR): A GINECO Phase II Trial Presenter: JM FerreroPresenter's Affiliation: GINECO, Paris, FranceType of Session: PosterBackground Previous studies have demonstrated that patients with ovarian cancer who have a time-to-relapse interval > 6 months retain sensitivity to...
Cancer Patients in US Nursing Homes: Quality of End of Life Care Presenter: V.M.P. JohnsonPresenter's Affiliation: Brown University Medical SchoolType of Session: ScientificBackground As the American population ages, increasing numbers of Americans are receiving their end of life care in nursing homes. Little...
Effect Of Nerve Stimulation Therapy On Chemotherapy Induced Emesis (Cie): A Randomized, Placebo Controlled Trial Evaluating The Efficacy Of The Reliefband (Rb) Device Presenter: Imad M TreishPresenter's Affiliation: University of North CarolinaType of Session: ScientificBackground Despite the improvements made in treating chemotherapy-induced nausea and vomiting (CINV), they remain some of patients' most feared...
Final Report of the Efficacy and Safety of the Anti-Epidermal Growth Factor Antibody, Cetuximab (IMC-C225), in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Refractory to Cisplatin Containing-Chemotherapy Presenter: Merrill S. KiesPresenter's Affiliation: MC Anderson Cancer CenterType of Session: PosterBackground Recurrent squamous cell cancer of the head and neck (SCCHN) is a clinical challenge, especially in the setting of disease that is refractory...
Issues in the Access of Promising New Cancer Agents "Miracle Cure for Cancer," "New Drug Gives Hope to Cancer Patients". Headlines like these make us cringe as health professionals, but are reported in the media on a daily basis, playing on the desperation of many cancer patients. Often times,...
Parenteral Opioid Rotation in Advanced Cancer Presenter: F.A. MahmoudPresenter's Affiliation: Cleveland Clinic FoundationType of Session: ScientificBackground Opioid side effects sometimes can limit upward titration of dosage to levels adequate for effective pain relief. Opioid rotation,...
Phase I Study of Docetaxel (D), Cisplatin (P), and Concomitant Boost Radiation for Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCHN) Presenter: B GlissonPresenter's Affiliation: MD Anderson Cancer Center, TexasType of Session: PosterBackground Both concurrent chemoradiation, with conventionally fractionated radiation (RT), and concomitant boost RT have been shown in randomized...
Phase III Quality Of Life (QOL) Study: Reduction In Hyposalivation Does Not Improve Qol For Head And Neck (H&N) Cancer Patients Post Radiation Therapy (P-Rt). Rtog 9709 Presenter: Jacquelyn J FisherPresenter's Affiliation: RTOGType of Session: ScientificBackground When radiation therapy treatment fields include the major salivary glands, many patients will experience dryness of the oral mucosa during the first 1 or...
Prostate Cancer Radiation Dose Response: Final Planned Analysis Of A Phase III Randomized Trial Presenter: Alan PollackPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Between 1993 and 1998, a randomized trial at MDACC was conducted to assess the effectiveness of two radiotherapy doses, 70 Gy versus 78 Gy,...
Prostate Cancer Radiation Dose Response: Final Planned Analysis Of A Phase III Randomized Trial Presenter: Alan PollackPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: PosterBackground Between 1993 and 1998, a randomized trial at MDACC was conducted to assess the effectiveness of two radiotherapy doses, 70 Gy...
Tumor microsatellite instability (MSI) and the benefit of 5-FU based chemotherapy in stage II & stage III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials Presenter: C.M. RibicPresenter's Affiliation: Lunenfeld Research InstituteType of Session: ScientificBackground Adding adjuvant chemoradiation therapy to resected T3-4 and N+ colon cancer increases survival, based on several large randomized studies....
Use of Low-dose Fractionated Radiation (LDFRT) as a Chemosensitizer of Neoadjuvant Paclitaxel (P) and Carboplatin (CBCDA) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Results of a New Treatment Paradigm Presenter: Susanne ArnoldPresenter's Affiliation: Markey Cancer Center, Lexington , KentuckyType of Session: PosterBackground Radiation resistance is a major cause of treatment failure in squamous cell cancer of the head and neck (SCCHN). Low dose...
Weekly Erythropoietin For Patients With Chemotherapy Induced Anemia: A Randomized, Placebo-Controlled Trial In The North Central Cancer Treatment Group Presenter: Peter T SilbersteinPresenter's Affiliation: The North Central Cancer Treatment Group RTOGType of Session: ScientificBackground Anemia occurs in a significant number of patients with cancer, and is associated with symptoms of fatigue,...
Weekly taxol (T) and carboplatin (P) as first-line therapy in advanced ovarian cancer (AOC): a phase II study Presenter: J. SehouliPresenter's Affiliation: North-East Society of Gynaecological Oncology (NOGGO), Berlin, GermanyType of Session: ScientificBackground Ovarian cancer often remains asymptomatic until it progresses to an advanced stage. This causes...